Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy.
10.1016/j.apsb.2023.02.004
- Author:
Wen ZHU
1
;
Yang WANG
1
;
Liangyin LV
1
;
Hui WANG
1
;
Wenqiang SHI
1
;
Zexin LIU
1
;
Mingzhe ZHOU
2
;
Jianwei ZHU
1
;
Huili LU
1
Author Information
1. Engineering Research Center of Cell and Therapeutic Antibody, Ministry of Education, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
2. State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai 200433, China.
- Publication Type:Journal Article
- Keywords:
Affinity;
CD16a;
CD32a;
CD64;
CRS;
Fcγ receptor;
IgG1 antibody;
Universal CAR-T cells
- From:
Acta Pharmaceutica Sinica B
2023;13(5):2071-2085
- CountryChina
- Language:English
-
Abstract:
Developing universal CARs with improved flexible targeting and controllable activities is urgently needed. While several studies have suggested the potential of CD16a in tandem with monoclonal antibodies to construct universal CAR-T cells, the weak affinity between them is one of the limiting factors for efficacy. Herein, we systematically investigated the impact of Fcγ receptor (FcγR) affinity on CAR-T cells properties by constructing universal CARs using Fcγ receptors with different affinities for IgG1 antibodies, namely CD16a, CD32a, and CD64. We demonstrated that the activities of these universal CAR-T cells on tumor cells could be redirected and regulated by IgG1 antibodies. In xenografted mice, 64CAR chimeric Jurkat cells with the highest affinity showed significant antitumor effects in combination with herceptin in the HER2 low expression U251 MG model. However, in the CD20 high expression Raji model, 64CAR caused excessive activation of CAR-T cells, which resulted in cytokine release syndrome (CRS) and the decline of antitumor activity, and 32CAR with a moderate affinity brought the best efficacy. Our work extended the knowledge about FcγR-based universal CAR-T cells and suggested that only the FcγRCAR with an appropriate affinity can offer the optimal antitumor advantages of CAR-T cells.
